Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast

Rhea-AI Summary

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on November 14, 2022, at 8:30 AM ET to discuss its third-quarter financial results. The company is focused on developing eganelisib, an innovative oral therapeutic aimed at reprogramming macrophages in cancer treatment. Clinical studies are underway, including MARIO-3, which examines eganelisib combined with Tecentriq® and Abraxane® in front-line advanced cancer patients, and MARIO-275, focused on urothelial cancer.

Positive

• Potential breakthrough in cancer treatment with eganelisib.
• Ongoing clinical studies for eganelisib indicate active development.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Monday, November 14, 2022, at 8:30 AM ET to report its financial results for the third quarter of 2022.

To access the conference call, please register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8. Upon registering, each participant will be provided with call details and access codes. All participants are encouraged to join 10 minutes prior to the start time. A live webcast of the conference call can be accessed from the Events & Presentations page in the Investors/Media section of Infinity’s website at www.infi.com. An archived version of the webcast will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. For more information on Infinity, please refer to Infinity's website at www.infi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005313/en/

Investor Relations:

Kevin Lui

Real Chemistry

klui@realchemistry.com

Source: Infinity Pharmaceuticals, Inc.

FAQ

When will Infinity Pharmaceuticals announce its Q3 2022 earnings?

Infinity Pharmaceuticals will announce its Q3 2022 earnings on November 14, 2022.

What is eganelisib and what is its purpose?

Eganelisib is a first-in-class, oral therapeutic designed to reprogram macrophages to combat immune suppression in cancer.

How can I access the conference call for Infinity Pharmaceuticals?

To access the conference call, register at https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8.

What are the main studies involving eganelisib?

The main studies are MARIO-3, assessing eganelisib with Tecentriq® and Abraxane®, and MARIO-275, focusing on opdivo® in urothelial cancer.